Parenteral Nutrition Market – Industry Analysis and Forecast (2024-2030) Trends, Statistics, Dynamics, Segment Analysis

The Parenteral Nutrition Market size was valued at USD 7.53 billion in 2023 and the total Parenteral Nutrition Market revenue is expected to grow at a CAGR of 5.82 % from 2024 to 2030, reaching nearly USD 11.19 billion.

Parenteral nutrition (PN), also known as intravenous feeding, is a method of feeding nutrients directly into the bloodstream when a patient is unable to get nutrition through the digestive tract. It's a form of feeding that bypasses the usual process of eating and digestion. PN is usually administered through a peripheral or central venous catheter and is primarily used when a patient cannot absorb nutrients by mouth or through enteral nutrition, typically due to illness, surgery, or other medical conditions. The solution is tailored to meet the patient's individual needs, containing the necessary macronutrients, micronutrients, vitamins, and minerals essential for maintaining health. It can be a life-saving intervention for patients who are unable to eat or tolerate enteral nutrition.

The rising prevalence of chronic diseases, increasing awareness regarding malnutrition, and the surging geriatric population. The factors contributing to Parenteral Nutrition Market growth are the growing demand for home healthcare, technological advancements in the pharmaceutical industry, and favorable reimbursement policies. The COVID-19 pandemic has also positively impacted market growth, with an increased emphasis on nutrition therapy and hospitalizations. Key players in the Parenteral Nutrition Market are focusing on strategic initiatives such as mergers and acquisitions, product launches, and collaborations to gain a competitive edge in the Parenteral Nutrition Market.

For instance, on April 5, 2022, Protara Therapeutics, Inc. announced alignment with the U.S. FDA on a registration path for IV Choline Chloride, expanding the patient population. Additionally, Baxter Healthcare Ltd. invested over $15 million to develop a modern aseptic compounding facility in Sandyford, Dublin, on July 26, 2022. This investment aims to increase domestic production capacity, enhance supply resiliency, and empower at-home patient treatment. These recent developments reflect the significant potential and growth opportunities in the Parenteral Nutrition Market.

The increasing incidence of chronic diseases such as cancer, gastrointestinal disorders, and neurological conditions is driving the demand for parenteral nutrition. The rising geriatric population, which is more prone to chronic diseases and malnutrition, is significantly contributing to the demand for parenteral nutrition products. Ongoing advancements in the pharmaceutical industry, particularly in the formulation of parenteral nutrition solutions, are driving market growth. There is an opportunity for the parenteral lipid emulsion segment to grow, as lipids are a vital component of parenteral nutrition, providing essential fatty acids and energy for patients. The development of single-dose amino acid solutions offers opportunities for Parenteral Nutrition Market growth, providing precise and tailored nutritional therapy for patients.To know about the Research Methodology :- Request Free Sample Report
Parenteral Nutrition Market Dynamics:
Increasing Prevalence of Chronic Diseases:

The rising incidence of chronic diseases, such as cancer, gastrointestinal disorders, and neurological diseases, is a significant driver for the parenteral nutrition market. Patients suffering from conditions like Crohn's disease or short bowel syndrome often require parenteral nutrition (PN) to meet their nutritional needs. For instance, according to the American Society for Parenteral and Enteral Nutrition (ASPEN), approximately 80% of patients on parenteral nutrition are choline deficient, which can lead to liver damage and hepatic failure. Proterra Therapeutics aligning with the FDA on a registrational path for IV Choline Chloride to address this issue is a notable example, with the potential to become the first FDA-approved IV choline therapy for the 40,000 PN patients in the U.S. This alignment significantly expands the addressable patient population and drives Parenteral Nutrition Market growth.

Technological advancements in parenteral nutrition products, such as the development of a modern aseptic compounding facility, contribute significantly to market growth. For example, Baxter Healthcare's investment in a modern aseptic compounding facility in Dublin increases domestic production capacity, enhances supply resiliency, and empowers at-home patient treatment. These advancements, including state-of-the-art technology and automated processes, enable faster translation of medication from concept to market, further fueling Parenteral Nutrition Market growth.

There is a growing emphasis on homecare settings for patient treatment, which drives the demand for parenteral nutrition products. Aseptic reconstitution by commercial providers plays a critical role in expanding home care. For instance, Baxter Healthcare's investment in an aseptic compounding facility in Dublin supports at-home patient treatment. Parenteral nutrition's role in the HSE National Community Intervention Team Outpatient Parenteral Antimicrobial Therapy Programme (OPAT) highlights the importance of homecare settings in driving market growth. The increasing geriatric population is a significant driver for the parenteral nutrition market. Elderly patients often require parental nutrition due to various health conditions, contributing to Parenteral Nutrition Market growth. The prevalence, causes, and consequences of disease-related malnutrition in the elderly underline the importance of medical nutrition. Parenteral nutrition is a crucial aspect of medical nutrition, emphasizing the significance of this demographic in driving Parenteral Nutrition Industry growth.Rising Demand for Personalized Medicine:

There is a rising demand for personalized medicine, which includes personalized parenteral nutrition formulations tailored to individual patient needs. The aseptic compounding process allows for patient-specific and batch, ready-to-use intravenous (IV) preparations. For example, Protara Therapeutics' plan to start a registrational trial to support FDA approval of IV Choline Chloride for PN patients in the first half of 2025 underscores the shift towards personalized medicine and drives Parenteral Nutrition Market growth. Increased healthcare expenditure, coupled with the growing focus on advanced medical treatments, propels the parenteral nutrition market. With significant investment from companies like Bayer and Baxter Healthcare, the market is expected to grow substantially. Bayer's investment in a new production facility and Baxter Healthcare's investment in a modern aseptic compounding facility in Dublin are prime examples of this trend, contributing to the growth of the parenteral nutrition market.

There is growing awareness about disease-related malnutrition, driving the demand for parenteral nutrition. Malnutrition continues to go undetected and untreated, posing a significant burden on the healthcare economy. However, a growing body of evidence demonstrates the benefits of medical nutrition, including parenteral nutrition, in addressing malnutrition. This awareness contributes to the increased adoption of parental nutrition, thus driving the Parenteral Nutrition Market growth. Government initiatives and supportive regulations further fuel the growth of the parenteral nutrition market.

For instance, Protara Therapeutics' alignment with the FDA on a registrational path for IV Choline Chloride highlights the government's role in addressing the unmet needs in parenteral nutrition. The FDA's recognition of the serious unmet need for IV choline for PN patients and its instrumental role in defining an efficient regulatory path support market growth by fostering innovation and development in the parenteral nutrition sector.

Table: Physiologic properties of TEs that are routinely included in Parenteral Nutrition (PN)



Trace Element (TE)
Physiologic Role


Chromium
Component of metalloenzymes and coenzyme in metabolic reactions associated with glucose homeostasis and insulin resistance


Copper
Enzymatic cofactor involved in connective tissue formation, hematopoiesis and iron metabolism, and CNS function


Manganese
Component of several metalloenzymes and required to activate enzymatic reactions involved in immune function, reproductive health, development of bone and connective tissue, neuronal function, and antioxidant activity


Selenium
Essential component of selenoproteins involved in anti-inflammatory, antioxidant, and immunological activity, as well as enzymes involved in regulating thyroid hormone metabolism


Zinc
Ubiquitous component of ~120 enzymes with catalytic, structural, and regulatory roles



Parenteral Nutrition Market Segment Analysis:
Based on the product, the various segments play a crucial role, including Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, and Vitamins & Minerals. The segment dominating market is Parenteral Lipid Emulsion due to its high demand for parenteral nutrition solutions. These lipid emulsions provide essential fatty acids and are widely used in intravenous nutrition. However, the segment expected to dominate in the near future is the Single Dose Amino Acid Solution segment. The increasing prevalence of chronic diseases and the rising demand for personalized medicine are driving the adoption of amino acid solutions. Amino acids play a vital role in the body's protein synthesis and are essential for patients requiring parenteral nutrition. The Vitamins & Minerals segment is also witnessing significant growth due to increasing awareness about disease-related malnutrition. With advancements in technology and an increasing focus on personalized medicine, these segments are anticipated to grow, meeting rising demand and improving patient outcomes in the Parenteral Nutrition Market.
Parenteral Nutrition Market Regional Insights:
North America dominates the Parenteral Nutrition Market. The U.S. leads this region due to high healthcare expenditures, increased awareness regarding malnutrition, and favorable reimbursement policies. Recent advancements in the pharmaceutical industry also contribute to market growth. For instance, on April 5, 2024, Protara Therapeutics, Inc. announced alignment with the U.S. FDA on a registration path for IV Choline Chloride, expanding the patient population. Moreover, the region is expected to witness significant growth due to the increasing prevalence of chronic diseases and the rising geriatric population.

Europe is another significant Parenteral Nutrition Market, with countries such as Germany, France, and the UK being major contributors. On November 23, 2023, Bayer inaugurated a new production facility for innovative parenteral products, investing 130 million EUR in Berlin, Germany. The investment is part of a billion-dollar program, strengthening Bayer's global pharmaceutical production network. Europe is expected to experience substantial growth due to increasing investments in healthcare infrastructure, technological advancements, and a rising geriatric population.

The Asia Pacific region is expected to witness the fastest growth in the Parenteral Nutrition Market. Countries like China, India, and Japan are significant contributors. For instance, Baxter Healthcare Ltd. invested over $15 million to develop a modern aseptic compounding facility in Sandyford, Dublin, on July 26, 2022. The investment aims to increase domestic production capacity, enhance supply resiliency, and empower at-home patient treatment. Asia Pacific is projected to grow due to increasing healthcare expenditure, rising awareness about malnutrition, and the growing demand for parenteral nutrition.
Competitive Landscape
Recent developments in the pharmaceutical industry are poised to significantly drive market growth. Protara Therapeutics' alignment with the FDA on a registrational path for IV Choline Chloride, broadening its use to include PN patients, addresses a critical unmet need. This move is set to fuel the Parenteral Nutrition Market, aiming to become the first FDA-approved IV choline therapy for PN patients in the U.S., potentially transforming the treatment landscape for approximately 40,000 patients. Similarly, Bayer's investment in a new production facility strengthens its global pharmaceutical production networks and innovative capabilities, promoting market growth. Baxter's investment in a modern aseptic compounding facility aligns with the HSE's carbon emission goals, enhancing supply resilience and empowering at-home patient treatment. These developments drive Parenteral Nutrition Market growth by addressing critical needs, enhancing production capacity, and fostering innovation, thus benefiting both patients and the industry.

April 5, 2024: Protara Therapeutics, Inc. aligns with the U.S. Food and Drug Administration (FDA) on a registration path for IV Choline Chloride, a phospholipid substrate replacement. Originally targeted for intestinal failure-associated liver disease (IFALD), it now broadens to include parenteral nutrition (PN) patients, unable to synthesize choline. The new development pathway significantly expands IV Choline Chloride's patient population, aiming to become the first FDA-approved IV choline therapy for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are choline deficient, which can lead to liver damage and hepatic failure. The company plans a registrational trial to support FDA approval in the first half of 2025.

November 23, 2023: Bayer inaugurates a new production facility for innovative parenteral products, investing 130 million EUR. The facility, part of a billion-dollar investment program, features state-of-the-art technology, including a robot-controlled, aseptic filling system, to expedite the translation of medication from concept to market. The event, held at Bayer's global pharmaceutical headquarters in Berlin, Germany, was attended by the Governing Mayor of Berlin, Kai Wegner, and Bayer Board Member Stefan Oelrich. This investment demonstrates Bayer's commitment to Berlin as an innovation hub and strengthens its global pharmaceutical production networks and innovative capabilities.

July 26, 2022: Baxter Healthcare Ltd. invests over $15 million to develop a modern aseptic compounding facility in Sandyford, Dublin. The investment aims to increase domestic production capacity, enhance supply resiliency, and empower at-home patient treatment. The first phase, with a good manufacturing practices (GMP) license from the Healthcare Products Regulatory Authority (HPRA), is completed. Construction on phase two is underway and expected to finish before year-end, subject to HPRA audit and approval. This investment, strengthening Baxter's more than 50-year history in Ireland, aligns with the Health Service Executive’s (HSE) carbon emission goals for 2050, reducing the need for importation.
Parenteral Nutrition Market Scope: Inquiry Before Buying



Parenteral Nutrition Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 7.53 Bn.


Forecast Period 2024 to 2030 CAGR:
5.82%
Market Size in 2030:
US $ 11.19 Bn.


 Segments Covered:
by Nutrient Type
Carbohydrates
Parenteral Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins & Minerals


by Patient Type
Adult
Paediatrics


by End-user
Hospitals
Clinics
Homecare
Other End-Users



Parenteral Nutrition Market Key Players:
North America:
1. Baxter (Deerfield, Illinois, United States)
2. Pfizer Inc. (Hospira Inc.) (New York, United States)
3. Allergan (Dublin, Ireland)

Europe:
4. B. Braun Melsungen AG (Melsungen, Germany)
5. Fresenius Kabi AG (Bad Homburg, Germany)
6. ViforPharma (Zurich, Switzerland)
7. Grifols, S.A. (Barcelona, Spain)
8. Actavis Inc. (Dublin, Ireland)

Asia Pacific:
9. Otsuka Pharmaceutical Factory, Inc. (Naruto, Japan)
10. Sichuan Kelun Pharmaceutical Co., Ltd. (Chengdu, China)
11. Aculife Healthcare (Ahmedabad, India)
12. Anhui Medipharm Co., Ltd. (Bozhou, China)
13. Amanta Healthcare (Mumbai, India)
FAQs:
1. What are the growth drivers for the Parenteral Nutrition Market?
Ans. Increasing Prevalence of Chronic Diseases and is expected to be the major driver for the Parenteral Nutrition Market.

2. What is the major Opportunity for the Parenteral Nutrition Market growth?
Ans. Rising Demand for Personalized Medicine is expected to be the major Opportunity in the Parenteral Nutrition Market.

3. Which country is expected to lead the global Parenteral Nutrition Market during the forecast period?
Ans. Europe is expected to lead the Parenteral Nutrition Market during the forecast period.

4. What is the projected market size and growth rate of the Parenteral Nutrition Market?
Ans. The Parenteral Nutrition Market size was valued at USD 7.53 billion in 2023 and the total Parenteral Nutrition Market revenue is expected to grow at a CAGR of 5.82 % from 2024 to 2030, reaching nearly USD 11.19 billion.

5. What segments are covered in the Parenteral Nutrition Market report?
Ans. The segments covered in the Parenteral Nutrition Market report are by Nutrient Type, Patient Type, End-user, and Region.